Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia

PURPOSE: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell proliferation and survival. Everolimus is an oral agent targeting raptor mTOR (mTORC1). The trial's goal was to determine the antitumor activity and safety of single-agent e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ghobrial, Irene M., Gertz, Morie, LaPlant, Betsy, Camoriano, John, Hayman, Suzanne, Lacy, Martha, Chuma, Stacey, Harris, Brianna, Leduc, Renee, Rourke, Meghan, Ansell, Stephen M., DeAngelo, Daniel, Dispenzieri, Angela, Bergsagel, Leif, Reeder, Craig, Anderson, Kenneth C., Richardson, Paul G., Treon, Steven P., Witzig, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2010
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2834498/
https://ncbi.nlm.nih.gov/pubmed/20142598
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.24.0994
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados